Direct Ras G12C Inhibitors: Crossing the Rubicon

Research output: Contribution to journalArticlepeer-review


Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered ‘undruggable’. In 2019 we will see the first clinical results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures.
Original languageEnglish
JournalBritish Journal of Cancer.
Early online date26 Jun 2019
Publication statusPublished - 2019

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Direct Ras G12C Inhibitors: Crossing the Rubicon'. Together they form a unique fingerprint.

Cite this